Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2007

01.05.2007 | Original Article

A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin

verfasst von: Chantal P. Bleeker-Rovers, Fidel J. Vos, Aart H. Mudde, Anton S. M. Dofferhoff, Lioe-Fee de Geus-Oei, Anton J. Rijnders, Paul F. M. Krabbe, Frans H. M. Corstens, Jos W. M. van der Meer, Wim J. G. Oyen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Since 18F-fluorodeoxyglucose (FDG) accumulates in neoplastic cells and in activated inflammatory cells, positron emission tomography (PET) with FDG could be valuable in diagnosing patients with fever of unknown origin (FUO). The aim of this study was to validate the use of FDG-PET as part of a structured diagnostic protocol in the general patient population with FUO.

Methods

From December 2003 to July 2005, 70 patients with FUO were recruited from one university hospital (n=38) and five community hospitals (n=32). A structured diagnostic protocol including FDG-PET was used. A dedicated, full-ring PET scanner was used for data acquisition. FDG-PET scans were interpreted by two staff members of the department of nuclear medicine without further clinical information. The final clinical diagnosis was used for comparison with the FDG-PET results.

Results

Of all scans, 33% were clinically helpful. The contribution of FDG-PET to the final diagnosis did not differ significantly between patients diagnosed in the university hospital and patients diagnosed in the community hospitals. FDG-PET contributed significantly more often to the final diagnosis in patients with continuous fever than in patients with periodic fever. FDG-PET was not helpful in any of the patients with normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Conclusion

FDG-PET is a valuable imaging technique as part of a diagnostic protocol in the general patient population with FUO and a raised ESR or CRP.
Literatur
1.
Barbado FJ, Vazquez JJ, Pena JM, Arnalich F, Ortiz-Vazquez J. Pyrexia of unknown origin: changing spectrum of diseases in two consecutive series. Postgrad Med J 1992;68:884–7.CrossRefPubMedPubMedCentral
2.
Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals. Clin Infect Dis 1992;15:968–73.CrossRefPubMed
3.
Knockaert DC, Vanneste LJ, Vanneste SB, Bobbaers HJ. Fever of unknown origin in the 1980s. An update of the diagnostic spectrum. Arch Intern Med 1992;152:51–5.CrossRefPubMed
4.
de Kleijn EM, van der Meer JW. Fever of unknown origin (FUO): report on 53 patients in a Dutch university hospital. Neth J Med 1995;47:54–60.CrossRefPubMed
5.
de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997;76:392–400.CrossRef
6.
Tabak F, Mert A, Celik AD, Ozaras R, Altiparmak MR, Ozturk R, et al. Fever of unknown origin in Turkey. Infection 2003;31:417–20.PubMed
7.
Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Dumez A, Blockmans D, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003;163:1033–41.CrossRefPubMed
8.
Saltoglu N, Tasova Y, Midikli D, Aksu HS, Sanli A, Dundar IH. Fever of unknown origin in Turkey: evaluation of 87 cases during a nine-year-period of study. J Infect 2004;48:81–5.CrossRefPubMed
9.
Ergonul O, Willke A, Azap A, Tekeli E. Revised definition of ‘fever of unknown origin’: limitations and opportunities. J Infect 2005;50:1–5.CrossRefPubMed
10.
Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000;30:150–85.CrossRefPubMed
11.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–80.PubMed
12.
Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995;36:1854–61.PubMed
13.
Blockmans D, Knockaert D, Maes A, De Caestecker J, Stroobants S, Bobbaers H, et al. Clinical value of [18F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001;32:191–6.CrossRefPubMed
14.
Meller J, Altenvoerde G, Munzel U, Jauho A, Behe M, Gratz S, et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med 2000;27:1617–25.CrossRefPubMed
15.
Lorenzen J, Buchert R, Bohuslavizki KH. Value of FDG PET in patients with fever of unknown origin. Nucl Med Commun 2001;22:779–83.CrossRefPubMed
16.
Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 2004;31:29–37.CrossRefPubMed
17.
Kjaer A, Lebech AM, Eigtved A, Hojgaard L. Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging 2004;31:622–6.CrossRefPubMed
18.
Buysschaert I, Vanderschueren S, Blockmans D, Mortelmans L, Knockaert D. Contribution of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur J Intern Med 2004;15:151–6.CrossRefPubMed
19.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.CrossRefPubMed
20.
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.CrossRefPubMed
21.
Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33:1114–21.CrossRefPubMed
22.
Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002;81:194–200.CrossRef
23.
24.
Kjaer A, Lebech AM. Diagnostic value of 111In-granulocyte scintigraphy in patients with fever of unknown origin. J Nucl Med 2002;43:140–4.PubMed
25.
de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging 2005;32:98–101.CrossRefPubMed
26.
Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des 2004;10:2935–50.CrossRefPubMed
27.
Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000;108:246–9.CrossRefPubMed
Metadaten
Titel
A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin
verfasst von
Chantal P. Bleeker-Rovers
Fidel J. Vos
Aart H. Mudde
Anton S. M. Dofferhoff
Lioe-Fee de Geus-Oei
Anton J. Rijnders
Paul F. M. Krabbe
Frans H. M. Corstens
Jos W. M. van der Meer
Wim J. G. Oyen
Publikationsdatum
01.05.2007
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0295-z

Weitere Artikel der Ausgabe 5/2007

European Journal of Nuclear Medicine and Molecular Imaging 5/2007 Zur Ausgabe

Society communications

Society communications

Image of the month

Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation

Original Article

Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis

Original article

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence

Book Review

Michael E. Phelps (ed) PET: physics, instrumentation and scanners. Springer, New York, 2006, 130 pp, 77 illustrations. Hardcover. $59.95. ISBN-10: 0-387-32302-3, ISBN-13: 978-0-387-32302-2

Review article

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”